Condition: Breast Cancer Invasive · Sponsor: University of Bonn
This pilot study will test the feasibility of using nanopore sequencing for breast cancer diagnosis in Tanzania. It aims to show that nanopore sequencing is non-inferior to the current standard of care, with the potential for faster and more cost-efficient results. By enhancing the speed and accuracy of diagnosis, this approach could improve treatment planning and outcomes for patients in resource-limited settings.
This description comes directly from the study's public registry record.
Oliver Henke, MD · +49 (0) 228 287 51521 · Oliver.Henke@ukbonn.de
Maximilian Rost, MD · +49 (0) 228 287 51521 · maximilian.rost@ukbonn.de
Always discuss trial participation with your own doctor first.
| Kilimanjaro Christian Medical Centre | Moshi, Tanzania | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06633276